David Maso - DocMorris Chief Board
| DOCM Stock | 5.70 0.10 1.79% |
Executive
David Maso is Chief Board of DocMorris AG
| Age | 55 |
| Address | WalzmUehlestrasse 49, Frauenfeld, Switzerland, 8500 |
| Phone | 41 52 724 00 20 |
| Web | https://corporate.docmorris.com/en |
DocMorris Management Efficiency
The company has return on total asset (ROA) of (0.077) % which means that it has lost $0.077 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2747) %, meaning that it generated substantial loss on money invested by shareholders. DocMorris' management efficiency ratios could be used to measure how well DocMorris manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to -0.37 in 2026. Return On Capital Employed is likely to climb to -0.17 in 2026. At this time, DocMorris' Non Currrent Assets Other are fairly stable compared to the past year. Other Current Assets is likely to climb to about 17.1 M in 2026, whereas Non Current Assets Total are likely to drop slightly above 342.2 M in 2026.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Oliver Kronenberg | Santhera Pharmaceuticals Holdin | 58 | |
| Dominik Arnold | Coltene Holding AG | 54 | |
| Robert Hendriks | Molecular Partners AG | N/A | |
| Ravi MD | Newron Pharmaceuticals SpA | 69 | |
| Renate Gloggner | Molecular Partners AG | 56 | |
| Brigitte Spolenak | Ascom Holding AG | N/A | |
| Martin Schlter | Coltene Holding AG | 54 | |
| Paul Frey | Coltene Holding AG | 51 | |
| Roberto Galli | Newron Pharmaceuticals SpA | N/A | |
| Oliver Strub | Santhera Pharmaceuticals Holdin | 63 | |
| Mattias Flodin | Coltene Holding AG | 52 | |
| Adam Novak | Ascom Holding AG | N/A | |
| Luc Gruner | Evolva Holding SA | 74 | |
| Lior Haalman | S H L | 59 | |
| Martin Steegmaier | Molecular Partners AG | N/A | |
| Bernd Altpeter | S H L | N/A | |
| Job Kamphuis | Ascom Holding AG | N/A | |
| Tobias Stanelle | Ascom Holding AG | N/A | |
| Geert MD | Santhera Pharmaceuticals Holdin | 66 | |
| Daniel Steiner | Molecular Partners AG | N/A | |
| Laura Faravelli | Newron Pharmaceuticals SpA | N/A | |
Management Performance
| Return On Equity | -0.27 | ||||
| Return On Asset | -0.077 |
DocMorris AG Leadership Team
Elected by the shareholders, the DocMorris' board of directors comprises two types of representatives: DocMorris inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DocMorris. The board's role is to monitor DocMorris' management team and ensure that shareholders' interests are well served. DocMorris' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DocMorris' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kaspar Niklaus, COO Board | ||
| Torben Bonnke, Director Communications | ||
| Walter Oberhansli, Founder Chairman | ||
| Daniel West, CFO Board | ||
| Pablo Gomez, CTO Board | ||
| Walter Hess, CEO Germany | ||
| David Maso, Chief Board | ||
| Andrea Skersies, Chief Board | ||
| Daniel Grigat, Group Sustainability |
DocMorris Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DocMorris a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.27 | ||||
| Return On Asset | -0.077 | ||||
| Profit Margin | (0.11) % | ||||
| Operating Margin | (0.1) % | ||||
| Current Valuation | 352.91 M | ||||
| Shares Outstanding | 48.6 M | ||||
| Shares Owned By Insiders | 17.33 % | ||||
| Shares Owned By Institutions | 22.29 % | ||||
| Price To Book | 0.62 X | ||||
| Price To Sales | 0.26 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for DocMorris Stock Analysis
When running DocMorris' price analysis, check to measure DocMorris' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DocMorris is operating at the current time. Most of DocMorris' value examination focuses on studying past and present price action to predict the probability of DocMorris' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DocMorris' price. Additionally, you may evaluate how the addition of DocMorris to your portfolios can decrease your overall portfolio volatility.